ATG9B and glioma: Silencing of ATG9b in mIDH1 human glioma cells (Supplementary Fig. 15a) and mIDH1 mouse NS models (Supplementary Fig. 15b-d) significantly reduced cell viability when combined with IR, compared to siRNA treatment alone (SJ-GBM2 mIDH1: P < 0.0001; CPAI mIDH1 mouse NS: P < 0.0001; RPAI mIDH1 NS: P < 0.0001; NPAI mIDH1 NS: P< 0.0001).